New data reveals significant benefits of Ozempic drug for kidney disease
Semaglutide, which is the main component of the obesity medication Wegovy, has been shown to reduce the risk of kidney failure and mortality in individuals diagnosed with diabetes.
People with kidney failure often need dialysis to help clean waste from their blood - Photo Reproduction/Mohammed Huwais/AFP via Getty
In recent years, the medical community has seen a significant increase in the use of innovative medications to treat a variety of chronic conditions. One of these medications, Ozempic (semaglutide), originally developed for the treatment of type 2 diabetes, has demonstrated additional surprising benefits. New studies indicate that Ozempic, in addition to being effective in treating obesity, can also have a substantial positive impact on kidney health, offering new hope for patients suffering from chronic kidney disease.
Researchers recently presented clinical trial data at a conference in Stockholm, demonstrating that the drug significantly reduces the risk of kidney failure and death in people with type 2 diabetes and chronic kidney disease. Scientists are excited about the results and believe the medication will eventually prove itself beneficial to a broader population of people with kidney disease. One of the researchers stated that this test is a first step towards that goal.
What is Ozempic?
Ozempic is an injectable medication that belongs to the class of GLP-1 (glucagon-like peptide-1) receptor agonists. Initially approved for controlling blood sugar levels in people with type 2 diabetes, Ozempic has also shown effectiveness in reducing body weight, which has made it a popular choice among endocrinologists.
Novo Nordisk, the semaglutide manufacturer based in Bagsværd, Denmark, announced in October last year that it had paused its kidney disease trial. The decision was based on the recommendation of an independent data safety monitoring board, which found the results to be extremely positive, making it unethical to continue giving placebos to some participants. Until now, the complete analysis of the data had not been released.
Recent Studies and Their Results
Recent research, published in renowned medical journals, has explored the effects of Ozempic beyond glycemic control. The most recent study published on May 24 in the British scientific journals Nature and The New England Journal of Medicine focused on patients with chronic kidney disease, a condition often associated with type 2 diabetes and hypertension. The phase IIIb trial, which involved 3,533 people, found that individuals who received weekly semaglutide injections were 24% less likely to experience "severe kidney disease events" such as kidney failure and death due to kidney complications. compared to those who received placebo.
Kidney failure occurs when one or both kidneys stop working on their own, requiring dialysis or kidney transplantation as treatment. Additionally, participants who received semaglutide were 29% less likely to die from heart attacks and other serious cardiovascular incidents, and 20% less likely to die from any cause during the trial period, compared to those who received placebo. This result is significant because "the links between kidney and heart disease are truly profound", says Samir Parikh, a nephrologist at the University of Texas Southwestern Medical Center in Dallas, who was not involved in the study.
Individuals with type 2 diabetes and chronic kidney disease often succumb to heart disease even before their kidney problems progress to failure. Parikh notes that chronic heart and kidney disease are closely intertwined and, unfortunately, tend to feed off each other. The addition of type 2 diabetes is like throwing "rocket fuel" on a fire, as this type of diabetes can cause damage to the body's small blood vessels, including those in the heart and kidneys.
“We are ecstatic that we are seeing real benefits” for people with chronic kidney disease, said Katherine Tuttle, a nephrologist at the University of Washington School of Medicine in Spokane who co-led the trial. “These patients benefit greatly.”
Clinical Implications
New data about Ozempic have significant implications for clinical practice. Doctors can now consider using this medication not only for the management of type 2 diabetes, but also as a strategy to protect patients' kidney health. This is particularly important for individuals who are at high risk of developing kidney failure.
According to Hertzel Gerstein, an endocrinologist at McMaster University in Hamilton, Canada, Previous studies already indicated that semaglutide, a blood glucose regulator, had the potential to protect the kidneys, although this research focused on evaluating its effects on other conditions, such as heart disease. However, doctors have seen kidney benefits in these studies. What sets this latest trial apart is its exclusive dedication to the progression of kidney disease, as Gerstein highlights.
Additionally, the current trial suggested that semaglutide may slow an individual's kidney deterioration. Participants who received the drug had a healthier estimated glomerular filtration rate, indicative of the kidneys' ability to filter waste, and lower urine albumin levels compared to those who received a placebo. Elevated albumin levels are an indicator of leaky blood vessels in the kidneys, which suggests a decline in kidney function.
The researchers responsible for the study say that it is still not completely clear why semaglutide benefits the kidneys. There may be several mechanisms at play, including a possible reduction in kidney inflammation, but more testing is needed to confirm this. In addition, other crucial questions remain, such as whether semaglutide can provide similar benefits to people with chronic kidney disease who do not have diabetes. Scientists also need to investigate how semaglutide compares to other medications used to treat chronic kidney disease, such as SGLT2 inhibitors, and whether combining these medications could result in additional benefits.
